“This is the first study in 11 years to show an improvement in survival with a new fist-line treatment option compared to sorafenib, which has been the standard of care throughout this time,” said study first author Ann-Lii Cheng, Director of the National Taiwan University Cancer Center, Taipei, Taiwan. He added, “Atezolizumab plus bevacizumab has the potential to be a practice-changing treatment option in hepatocellular carcinoma.”
歐洲腫瘤醫學會（ESMO）於2019年11月22日在新加坡舉行亞洲年會，台灣大學醫學院附設癌醫中心醫院院長- 鄭安理教授，發表一項關於晚期肝癌治療的重大成果，第一線使用免疫治療合併抗血管新生標靶藥物，可延病人存活期，是暌違11年來重大突破!